By sharon-mccutcheon-FEPfs43yiPE-unsplash

NHSBSA publishes latest Innovation Scorecard for the NHS in England

The NHS Business Services Authority (NHSBSA) has published the latest Innovation Scorecard as an Official Statistic, after taking on the responsibility from NHS England who previously produced and published the publication.

The latest Innovation Scorecard shows that there was a 73.1% increase in prescribed medicines from January 2023 to December 2023 compared to the previous 12 months. During the same period, 15 medicine groupings were used more frequently than in the previous 12 months.

The Innovation Scorecard is presented in an interactive dashboard format and reports on the use of individual medicines and medicine technologies in the NHS in England which have been positively appraised by the National Institute for Health and Care Excellence (NICE).

The scorecard aims to improve transparency within the NHS of what treatments recommended by NICE are available at a local level, including Trusts, Integrated Care Systems (ICBs), as well as national and NHS England Region levels. It can be used by local NHS organisations to monitor progress in implementing NICE Technology Appraisal (TA) recommendations.

190 medicines are analysed in the scorecard. These medicines include 17 medicine groupings which combine the use of different treatment options used to treat the same condition. The medicine groupings are for:

  • direct oral anticoagulants (DOACs) for the prevention of stroke in both primary and secondary care
  • multiple sclerosis
  • cystic fibrosis
  • smoking cessation
  • severe asthma
  • acute coronary syndrome
  • hepatitis C
  • metastatic prostate cancer
  • migraine
  • epidermal growth factor receptor (EGFR) non-small-cell lung cancer
  • hypercholesterolaemia
  • COVID-19
  • hereditary transthyretin amyloidosis (hATTR) polyneuropathy
  • obesity
  • use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors
  • use of icosapent ethyl

To access the full publication, go to:

Contact Information

Rosie Moorhouse

Media and Campaigns Officer

NHS Business Services Authority

Notes to editors

The NHS Business Services Authority is an Arm’s Length Body of the Department of Health and Social Care. We manage over £48 billion of NHS spend annually, delivering a range of national services to NHS organisations, NHS contractors, patients and the public. Our purpose is to be a catalyst for better health and our vision is to be the delivery partner of choice for the NHS.

For more information about the NHSBSA, please visit


Considerations for interpreting the data:

  • medicines can be used to treat multiple conditions
  • a condition can be treated with various medicines
  • one medicine may displace another, for example, an older class of medicine will show a large decrease in contrast to a newer class of medicine that has increased in use
  • for a typical uptake curve the rate of increase is rapid in the early years but eases off over time
  • year on year comparisons of the volume of medicine use may have been impacted by the effects of COVID